Newron Pharmaceuticals is making significant headway in progressing its drug candidate, evenamide, to become an effective treatment option for patients suffering with treatment-resistant schizophrenia (TRS). The latest update from the company confirmed that the registrational ENIGMA-TRS Phase III p
02 Jul 2025
Newron Pharmaceuticals:Evenamide enters ENIGMA-TRS programme
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Newron Pharmaceuticals:Evenamide enters ENIGMA-TRS programme
Newron Pharmaceuticals S.p.A. (NWRN:SWX) | 0 0 0.0%
- Published:
02 Jul 2025 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
15 -
Newron Pharmaceuticals is making significant headway in progressing its drug candidate, evenamide, to become an effective treatment option for patients suffering with treatment-resistant schizophrenia (TRS). The latest update from the company confirmed that the registrational ENIGMA-TRS Phase III p